FindTrial
Sign In

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

DRUG4 trials

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC, Institut Català d'Oncologia, Arbeitsgemeinschaft medikamentoese Tumortherapie, University of Colorado, Denver

Conditions

Bone Giant Cell TumorBreast Neoplasm FemaleCarcinoma, Non-Small-Cell LungHormone Receptor Negative NeoplasmHormone Receptor Positive TumorMultiple MyelomaStage I Breast CancerStage II Breast Cancer

Early Phase 1

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
NCT03691311
Institut Català d'OncologiaBreast Neoplasm Female, Hormone Receptor Negative Neoplasm, Hormone Receptor Positive Tumor +2
Start: 2018-07-05End: 2023-02-05Target: 60Updated: 2021-11-03

Phase 2

Reduced Dose-density of Denosumab for Unresectable GCTB
TerminatedNCT03620149
European Organisation for Research and Treatment of Cancer - EORTCBone Giant Cell Tumor
Start: 2019-09-26End: 2020-07-30Updated: 2021-01-06
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
CompletedNCT03792763
Arbeitsgemeinschaft medikamentoese TumortherapieMultiple Myeloma
Start: 2019-09-30End: 2023-09-14Updated: 2025-02-11

Unknown Phase

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
RecruitingNCT03958565
University of Colorado, DenverCarcinoma, Non-Small-Cell Lung
Start: 2020-04-28End: 2028-04-28Target: 100Updated: 2026-06-03

Related Papers

Abstract P1-02-17: Rediscovering Denosumab: Immunomodulation of the Tumor Microenvironment in Early-Stage Breast Cancer through RANK Pathway Inhibition
Clinical Cancer Research2025-06-13
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.
2025-05-122 citations
Abstract PS16-04: Denosumab as an enhancer of the immune infiltrate in hormone receptor-positive early breast cancer. Subgroup analysis from the D-Biomark window-of-opportunity clinical trial (NCT03691311)
Cancer Research2024-05-02
Abstract P2-08-10: First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer
Cancer Research2022-02-15
Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.
2021-12-2824 citations
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells
Nature Communications2020-12-1080 citations